Figures published by the EMA in October 2010 on centralised procedures show a reduction in the number of generic applications filed and finalised this year up to September 2010. Although this number will undoubtedly increase by the end of the year, a marked difference is already evident in comparison to 2008 and 2009, when 30 and 38 generic applications, respectively, were filed compared to only 13 filed in 2010.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
-
Biosimilars
News
- EC approvals of four biosimilars: Tofidence, Wezenla, Avzivi and SteQeyma
- Canada approves trastuzumab Adheroza and ustekinumab Steqeyma biosimilars
- EMA recommends approval of ranibizumab, rituximab and trastuzumab biosimilars
- COFEPRIS approves bevacizumab Bhava and trastuzumab Mamitra biocomparables
Research
- Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
- Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
- Biosimilars in inflammatory bowel disease: are we ready for multiple switches
- Topline results from clinical development programme for candidate biosimilar AVT05 golimumab
- MORE EDITORIAL SECTIONS
- Search
Comments (0)
Post your comment